Windtree Therapeutics, Inc.
WINT
$0.456
$0.08623.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.26% | -37.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.31% | -17.30% | |||
| Operating Income | -4.31% | 17.30% | |||
| Income Before Tax | -250.37% | 190.00% | |||
| Income Tax Expenses | -- | 67.92% | |||
| Earnings from Continuing Operations | -246.19% | 200.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -246.19% | 200.65% | |||
| EBIT | -4.31% | 17.30% | |||
| EBITDA | -4.44% | 16.92% | |||
| EPS Basic | -1,270.17% | 100.19% | |||
| Normalized Basic EPS | -114.22% | 115.07% | |||
| EPS Diluted | -1,270.17% | 100.19% | |||
| Normalized Diluted EPS | -114.22% | 115.07% | |||
| Average Basic Shares Outstanding | 533.64% | 870.62% | |||
| Average Diluted Shares Outstanding | 533.64% | 870.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.20% | 1.89% | |||